Filing Flows › Supernus Pharmaceuticals (SUPN) › Recalls, complaints & regulation
Supernus Pharmaceuticals (SUPN): recalls and clinical trials
Supernus Pharmaceuticals (SUPN) beyond its filings: 2 recalls in the last 12 months (2 in five years, 0 Class I); 8 active clinical trials.
Latest recalls
- 2026-09-09 · FDA drug · Trokendi XR, (topiramate) extended-release capsules, 50 mg, 30 Capsules, Rx only, Manufactured by: Catalent Pharma Solutions, Winchester, KY 40391 USA, Manufact
- 2026-07-29 · FDA drug · Trokendi XR, topiramate extended-release capsules, 25mg, 30 Capsules, Rx only, Manufactured by: Catalent Pharma Solutions, Winchester, KY 40391 USA, Manufacture
Supernus Pharmaceuticals' latest quarter
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
Questions
Has Supernus Pharmaceuticals had any recalls?
2 recalls on file over five years from the FDA, CPSC and NHTSA; 2 in the last 12 months.
How many clinical trials does Supernus Pharmaceuticals have?
8 active studies on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.